{
  "report_rows": [
    {
      "kpi": "Core FFO/share",
      "prediction": "IN-LINE",
      "answer": "pred $1.630 vs. cons $1.632",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating occupancy",
      "prediction": "MISS",
      "answer": "pred 85.50% vs. cons 86.56%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Same-store NOI growth",
      "prediction": "MISS",
      "answer": "pred -12.0% vs. cons -10.92%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Core FFO/share",
      "prediction": "UNCHANGED",
      "answer": "guide $6.30-$6.50 vs. cons $6.360",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 year-end operating occupancy",
      "prediction": "UNCHANGED",
      "answer": "guide 86.2%-87.8% vs. cons 87.09%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 same-store NOI growth",
      "prediction": "BETTER",
      "answer": "guide (10.5)%-(8.5)% vs. cons -10.61%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2H26 leasing / life-science demand commentary",
      "prediction": "LOWER",
      "answer": "guide selective public-biotech demand and limited Q2 vacancy offset vs. cons UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -5.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -6.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 weak operating exit-rate pressures revisions",
  "day5_confidence": "LOW"
}